JMJD3 also regulates tumor immunity in CRC by enabling the transcription of the Th-1 type chemokine (CXCL9 and CXCL10), and treating the primary cells of CRC with GSK-J4 leads to a reduction in the chemokine level. Here, CXCL9 is linked to colorectal carcinoma.